Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-17T14:03:24.469Z Has data issue: false hasContentIssue false
  • English
  • Français

New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention

Published online by Cambridge University Press:  02 December 2014

David J. Gladstone ,
Karen M. Earl ,
Tammy J. Bungard ,
Jafna L. Cox ,
Alan Bell ,
Paul Dorian ,
Naeem Dean ,
Thao Huynh ,
Anil Chopra  and
John Eikelboom
...Show all authors
David J. Gladstone*
Affiliation:
Regional Stroke Centre and Division of Neurology, Department of Medicine and Brain Sciences Program, University of Toronto
Karen M. Earl
Affiliation:
EBM Consulting, Inc., Oakville, Ontario
Tammy J. Bungard
Affiliation:
Anticoagulation Management Service, Division of Cardiology, University of Alberta, Edmonton
Jafna L. Cox
Affiliation:
Division of Cardiology, Departments of Medicine and Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia
Alan Bell
Affiliation:
Department of Family Medicine, University of Toronto
Paul Dorian
Affiliation:
Division of Cardiology, St Michael's Hospital and Department of Medicine, University of Toronto
Naeem Dean
Affiliation:
Stroke Program, Royal Alexandra Hospital
Thao Huynh
Affiliation:
Division of Cardiology, McGill Health University Center, Montreal
Anil Chopra
Affiliation:
Emergency Medicine, and Department of Medicine, University Health Network, Toronto
John Eikelboom
Affiliation:
Department of Medicine, McMaster University, Hamilton
Ashfaq Shuaib
Affiliation:
Division of Neurology, University of Alberta Hospital, Edmonton, Alberta
*
Regional Stroke Prevention Clinic, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room A442, Toronto, Ontario, M4N 3M5, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 5 , September 2011 , pp. 777 - 782
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1.Public Health Agency of Canada. 2009 Tracking Heart Disease and Stroke in Canada [Internet]. [cited 2011Mar 21]. Available from: http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/indexeng.phpGoogle Scholar
2.Gladstone, DJ, Blakely, J, Dorian, P, et al.Detecting paroxysmal atrial fibrillation after ischemic stroke and transient ischemic attack: if you don’t look, you won’t find. Stroke. 2008;39:e78–9.CrossRefGoogle ScholarPubMed
3.Statistics Canada. Table 4 Population estimates by sex and age group as of July 1, 2010, Canada [Internet]. [cited 2011 Mar 21]. Available from: http://www.statcan.gc.ca/daily-quotidien/100929/dq100929b-eng.htmGoogle Scholar
4.Statistics Canada. Projected population by age group according to three projection secenarios at July 1, 2036 [Internet]. [cited 2011 Mar 21]. Available from: http://www40.statcan.gc.ca/l01/cst01/demo08d-eng.htmGoogle Scholar
5.Santini, M, Ricci, RP.The worldwide social burden of atrial fibrillation: what should be done and where do we go? J Interv Card Electrophysiol. 2006 Dec;17(3):183–8.CrossRefGoogle ScholarPubMed
6.Hart, RG, Pearce, LA, Agullar, MI.Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRefGoogle ScholarPubMed
7.Zimetbaum, PJ, Thosani, A, Yu, HT, et al.Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123:446–53.CrossRefGoogle ScholarPubMed
8.van Walraven, C, Jennings, A, Oake, N, Fergusson, D, Forster, AJ.Effect of study setting on anticoagulation control. A systematic review and metaregression. Chest. 2006;129:1155–66.CrossRefGoogle ScholarPubMed
9.Matchar, DB, Samsa, GP, Cohen, SJ, Oddone, EZ, Jurgelski, AE.Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113(1): 42–51.CrossRefGoogle ScholarPubMed
10.Gladstone, DJ, Bui, E, Fang, J, et al.Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:235–40.CrossRefGoogle Scholar
11.O’Donnell, M, Oczkowski, W, Fang, J, et al.Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5(9):749–54.CrossRefGoogle ScholarPubMed
12.Connolly, SJ, Pogue, J, Eikelboom, J, et al.Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.CrossRefGoogle ScholarPubMed
13.Bungard, TJ, Gardner, L, Archer, S, et al.Evaluation of a pharmacist-managed anticoagulation clinic - improving patient care. Open Medicine. 2009;3(1):16–21.Google ScholarPubMed
14.Bungard, TJ, Ackman, ML, Ho, G, Tsuyuki, RT.Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy. 2000;20(9):1060–5.CrossRefGoogle ScholarPubMed
15.Mariano, Z, Triveri, M, Atzema, C, Dorian, P.Utilization of anticoagulant therapy in the emergency department for patients with atrial fibrillation at high risk of stroke [abstract]. Can J Cardiol. 2009;25 Suppl B:S301.Google Scholar
16.Glader, EL, Sjolander, M, Eriksson, M, Lundberg, M.Persistent use of secondary prevention drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397–401.CrossRefGoogle ScholarPubMed
17.Gallagher, AM, Rietbrock, S, Plumb, J, Van Staa, TP.Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in clinical practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6:1500–6.CrossRefGoogle ScholarPubMed
18.Budnitz, DS, Pollock, DA, Weidenbach, KN, Mendelsohn, AB, Schroeder, TJ, Annest, JL.National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–66.CrossRefGoogle ScholarPubMed
19.Bungard, TJ, Ghali, WA, McAlister, , et al.Physicians’ perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ. 2001;165(3):301–2.Google ScholarPubMed
20.Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51.CrossRefGoogle ScholarPubMed
20a.Eikelboom, JW, Wallentin, L, Connolly, SJ, et al.Risk of bleeding with 2 doses of Dabigatran compared with Warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation 2011;123(21):2363–72.CrossRefGoogle ScholarPubMed
21.Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al.Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–6.CrossRefGoogle ScholarPubMed
22.Mahaffey, KW, Fox, KAA, ROCKETAF Investigators. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Presented, AHA Nov. 15, 2010. Available from: http://www.dtmi.duke.edu/website-administration/files/ROCKET-AF-LBCT-FINAL.ppt/viewGoogle Scholar
23.Connolly, SJ, Eikelboom, J, Joyner, C, et al.Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.CrossRefGoogle ScholarPubMed
24.Camm, AJ, Kirchhof, P, Lip, GYH, et al.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.Google ScholarPubMed
25.Cairns, JA, Connolly, SJ, McMurtry, S, Stephenson, M, Talajic, M, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):74–90.CrossRefGoogle Scholar
26.Lindsay, MP, Gubitz, G, Bayley, M, Hill, MD, Davies-Schinkel, C, Singh, S, Phillips, S.Canadian best practice recommendations for stroke care (update 2010). On behalf of the Canadian Stroke Strategy Best Practices and Standards Writing Group. 2010; Ottawa, Ontario Canada: Canadian Stroke Network. [cited 2011 Mar 21]. Available from: http://www.strokebestpractices.caGoogle Scholar
27.U.S. Food and Drug Administration. FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules [Internet]. [cited 2011 Apr 6]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm248746.htmGoogle Scholar
28.Bungard, TJ, Bucci, C, Kertland, H, Pickering, J, Semchuk, WM.Preventing stroke in atrial fibrillation patients: a systematic approach. Can Pharm J. [In Press 2011].CrossRefGoogle Scholar